1. South Korea Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
KBIO LABS Inc.

KBIO LABS Inc.

KKRX:038530
3,260.00
KRW
-35.00
(-1.06%)
-150.50EPS
195.19BMarket Cap
KBIO LABS Inc.
KRX:038530
(Korea Stock Exchange)

Recent

price

3,260.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
15,814.39
16,864.26
15,143.62
10,055.49
19,392.47
13,915.32
5,985.35
2,647
3,094.27
1,968.76
583.92
564.56
1,705.66
1,336.66
3,323.55
3,820.39
4,471.92
Revenue per Share
601.25
1,486.29
367.43
-13,160.75
-8,951.98
-7,628.43
-14,628.31
-507.72
-2,374.44
-5,495
-170
-1,260
-420
-620
-295
-140
-126.62
Basic EPS, GAAP
-3,199.84
-13,168.51
-8,238.54
-13,978.24
-6,382.34
-6,649.27
-4,282.23
-1,291.41
-2,496.08
-678.5
367.32
-89.67
206.48
-71.96
-8.27
354.32
420.1
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
31,419.89
32,981.39
33,394.17
21,241.54
15,017.31
13,410.96
1,083.27
2,702.85
5,869.77
3,113.73
4,513.89
3,791.95
3,638.27
2,737.64
2,438.54
2,305.61
2,329.66
Book Value per Share
29,205.02
30,340.24
30,748.75
14,469.29
9,070.7
10,636.99
-67.14
1,395.72
5,633.24
2,743.51
4,333.38
3,531.9
3,427.56
2,587.15
2,432.47
2,246.26
2,264.19
Tangible Book Value per Share
1
1
1
1
1
1
2
2
2
6
9
15
18
20
23
23
18
Basic Weighted Avg Shares
10,718
11,237
10,491
7,168
16,486
18,635
9,588
5,031
5,708
11,323
5,146
8,722
31,129
27,325
76,514
87,312
82,639
Sales/Revenue/Turnover
7.22
15.33
6.93
-85.63
-35.3
-44.21
-88.91
18.63
-15.84
-30.21
-16.97
-54.81
1.46
-2.05
1.06
1.74
0.47
Operating Margin (%)
601
1,550
2,357
2,586
2,601
2,183
1,204
110
211
517
641
674
592
491
1,084
938
945
Depreciation Expense
407
990
255
-9,381
-7,610
-10,216
-23,433
-965
-4,380
-31,604
-1,498
-19,466
-7,665
-12,674
-6,791
-3,200
-2,340
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
3.8
8.81
2.43
-130.88
-46.16
-54.82
-244.4
-19.18
-76.74
-279.11
-29.11
-223.18
-24.62
-46.38
-8.88
-3.66
-2.83
Profit Margin (%)
15,519
12,627
15,448
5,932
5,953
10,216
-1,245
-3,533
11,799
-22,001
30,775
40,459
35,232
61,576
61,030
68,132
69,009
Working Capital
- -
2,907
3,067
6,175
6,915
1,750
1,303
- -
5,440
1,420
135
166
118
2,535
358
211
186
LT Debt
21,014
21,830
22,928
16,191
16,568
21,193
1,890
5,364
20,087
21,069
59,738
62,984
66,798
128,331
107,082
102,281
104,466
Total Equity
3.72
7.55
2.76
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
1.96
4.86
2
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
1.96
4.62
1.14
-47.96
-47.77
-55.42
-203.04
-26.61
-34.42
-153.58
-3.71
-31.72
-11.81
-19.49
-11.36
-5.84
-4.25
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
527
375
629
LT Borrowings
- -
- -
- -
LT Finance Leases
248
211
186
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
23
Market Capitalization
144,949
139,174
195,190

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
69,443
84,352
83,265
Cash, Cash Equivalents & STI
53,881
65,434
64,739
Accounts Receivable, Net
4,687
9,177
6,542
Inventories
5,456
6,193
5,404
Total Current Liabilities
7,572
16,220
14,257
Payables & Accruals
- -
- -
- -
ST Debt
527
375
629
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
63.82%
16.51%
-4.48%
Free Cash Flow
-529.31%
-1,019.06%
-4,354.39%
Net Income, GAAP
201.84%
220.96%
-52.89%
Sales/Revenue/Turnover
46.95%
101.66%
14.11%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
16,044
19,022
16,522
24,926
76,514
2025
20,542
20,799
17,582
28,389
87,312
2026
15,869
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.4
140
5
-2,188.38
-295
2025
-10
-80.08
-12.37
-180.76
-140
2026
27.31
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
KBIO LABS Inc. is a South Korea-based technology and life sciences enterprise primarily engaged in the distribution of biotechnology laboratory products and the development of intelligent video surveillance and public safety solutions. Founded in 1997 and headquartered in Seoul, South Korea, the company operates across two core business segments: Bio Distribution and Information & Communication Technology (ICT) Security. In its Bio Distribution division, the company imports, distributes, and supplies life science research equipment; laboratory instruments; specialized bio-reagents; molecular biology consumables; diagnostic assay kits; and chemical materials to academic universities, hospital medical research centers, private laboratories, and biotechnology research institutions across Seoul and the Gyeonggi metropolitan region. In its ICT Security division, KBIO LABS develops and manufactures digital video recorders (DVRs); network video surveillance systems; closed-circuit television (CCTV) hardware; video management software; IoT-integrated smart safety platforms; Mobile Application Patrol (MAP) systems; smart police dispatch integration systems; and municipal safe-return public safety service solutions. In recent developments, the company underwent a corporate rebranding in early 2026, changing its name from KBio Company Inc. to KBIO LABS Inc. to align its corporate identity with its specialized focus on laboratory distribution and advanced research solutions. Over the past two years, the enterprise executed capital restructuring measures, including reverse stock split actions to enhance shareholder equity structure, while expanding authorized distribution partnerships with international life science manufacturers and accelerating the integration of IoT and artificial intelligence technologies into its municipal public safety software suite.